Skip Nav Destination
Issues
1 November 2020
-
Cover Image
Cover Image
Tumor development and progression hinge upon ongoing co-evolution and crosstalk with the tumor microenvironment. In particular, fibroblasts in the stromal compartment are co-opted to support tumor growth and survival through heterotypic interactions with tumor cells. The cover depicts a novel co-culture method in which breast cancer organoids (white) are seeded alongside autologous cancer-associated fibroblasts (red). Using this new model, the authors demonstrate persistent tumor—stroma interactions that regulate the molecular phenotype and aggressiveness of cancer cells. For more information, see the Highlight on page 1613 and the article on page 1615. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1541-7786
EISSN 1557-3125
Molecular Cancer Research
Table of Contents
Highlights
Rapid Impact
Cancer Genes and Networks
Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer
Daniel R. Goulet; Joseph P. Foster, II; Jon S. Zawistowski; Samantha M. Bevill; Mélodie P. Noël; José F. Olivares-Quintero; Noah Sciaky; Darshan Singh; Charlene Santos; Samantha G. Pattenden; Ian J. Davis; Gary L. Johnson
Genome Maintenance
Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A Is Mediated by Replication Protein A in Ovarian Cancer
Shruthi Sriramkumar; Timothy D. Matthews; Ahmed H. Ghobashi; Samuel A. Miller; Pamela S. VanderVere-Carozza; Katherine S. Pawelczak; Kenneth P. Nephew; John J. Turchi; Heather M. O'Hagan
RNA Biology
Signal Transduction and Functional Imaging
Tumor Microenvironment and Immunobiology
Letters to the Editor
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.